Adenowire
TRANSFORMING THE TREATMENT OF
Heart Attacks
THE ADENOSINE-RELEASING GUIDEWIRE PREVENTS AND TREATS MVO, THUS GREATLY IMPROVING PATIENT OUTCOMES IN PATIENTS UNDERGOING PCI.
BY PROVIDING ADENOSINE DIRECTLY TO THE AT-RISK MYOCARDIUM, ADENOWIRES WILL IMPROVE PCI SAFETY, SHORTEN PROCEDURE TIMES AND AVOID THE NEED FOR ADDITIONAL DRUG USE.
THE FDA HAS ALREADY APPROVED GUIDEWIRES AND ADENOSINE WHICH SHOULD FACILITATE FDA APPROVAL OF ADENOWIRES.
CURRENT SOLUTION
A revolutionary platform concept which can be expanded to include intravascular deliver of any drug.
Since guidewires are mandatory PCI devices, Adenowires can be used without thought or changes in practice.
Adenowires provide safe, convenient, targeted, continuous and autonomous treatment of the "at risk" myocardium with adenosine (a coronary vasodilator, antiplatelet drug and anti-inflammatory agent).
Adenowires overcome a barrier to treating patients with adenosine, namely that in human blood adenosine is eliminated in 1 second.
THE ADENOPAINT ROADMAP
ADENOWIRE™ DEVELOPMENT ROADMAP
1990-2010
Animal and clinical studies verify efficacy of adenosine infusion to reduce heart muscle damage
2010
Adenopaint formed to develop adenosine based technologies
2010-2014
Development of first generation adenosine coated guidewire.
Patent issued in US, Canada & Europe
2014-2019
Development of second generation adenosine device utilizing novel guidewire platform and coating
2019-2021
Verification of efficacy in bench and large animal studies
2022
Additional Patent obtained for new coating formulation and wire design
Product development
"DE-Novo" Device Classification
2023
Contract Manufacturer to meet regulatory approval requirements for clinical studies
Raised $1M Seed Round
